Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) Short Interest Down 12.8% in February

Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) was the recipient of a significant decline in short interest in the month of February. As of February 27th, there was short interest totaling 4,572,652 shares, a decline of 12.8% from the February 12th total of 5,244,475 shares. Approximately 3.5% of the company’s shares are sold short. Based on an average daily trading volume, of 1,025,083 shares, the short-interest ratio is currently 4.5 days. Based on an average daily trading volume, of 1,025,083 shares, the short-interest ratio is currently 4.5 days. Approximately 3.5% of the company’s shares are sold short.

Wall Street Analysts Forecast Growth

Several brokerages have recently issued reports on ALNY. Chardan Capital cut their target price on shares of Alnylam Pharmaceuticals from $475.00 to $425.00 and set a “buy” rating on the stock in a report on Friday, February 13th. Oppenheimer began coverage on shares of Alnylam Pharmaceuticals in a research report on Wednesday, January 7th. They set an “outperform” rating and a $500.00 price target for the company. Weiss Ratings raised shares of Alnylam Pharmaceuticals from a “sell (d-)” rating to a “hold (c-)” rating in a report on Thursday, January 15th. Jefferies Financial Group restated a “hold” rating and issued a $330.00 price objective (down from $522.00) on shares of Alnylam Pharmaceuticals in a research report on Monday. Finally, Needham & Company LLC lowered their price objective on shares of Alnylam Pharmaceuticals from $529.00 to $510.00 and set a “buy” rating for the company in a research note on Thursday, February 12th. One research analyst has rated the stock with a Strong Buy rating, twenty-one have assigned a Buy rating and six have given a Hold rating to the stock. According to MarketBeat.com, the company has an average rating of “Moderate Buy” and an average price target of $468.84.

Alnylam Pharmaceuticals Price Performance

Shares of Alnylam Pharmaceuticals stock opened at $318.91 on Tuesday. The business has a 50 day moving average of $342.78 and a 200 day moving average of $408.50. Alnylam Pharmaceuticals has a 52 week low of $205.87 and a 52 week high of $495.55. The company has a market cap of $42.29 billion, a PE ratio of 186.50 and a beta of 0.36. The company has a quick ratio of 2.71, a current ratio of 2.76 and a debt-to-equity ratio of 1.28.

Alnylam Pharmaceuticals (NASDAQ:ALNY) last issued its quarterly earnings data on Thursday, February 12th. The biopharmaceutical company reported $1.25 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $1.43 by ($0.18). Alnylam Pharmaceuticals had a net margin of 6.43% and a return on equity of 69.02%. The company had revenue of $1.10 billion for the quarter, compared to analysts’ expectations of $1.16 billion. During the same period in the previous year, the firm posted ($0.65) earnings per share. The firm’s revenue for the quarter was up 84.9% compared to the same quarter last year. As a group, equities research analysts forecast that Alnylam Pharmaceuticals will post -1.7 earnings per share for the current year.

Insider Buying and Selling

In other Alnylam Pharmaceuticals news, EVP Kevin Joseph Fitzgerald sold 1,652 shares of Alnylam Pharmaceuticals stock in a transaction that occurred on Tuesday, March 3rd. The stock was sold at an average price of $319.73, for a total value of $528,193.96. Following the transaction, the executive vice president directly owned 21,860 shares of the company’s stock, valued at $6,989,297.80. The trade was a 7.03% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, EVP Pushkal Garg sold 1,775 shares of the business’s stock in a transaction that occurred on Tuesday, March 3rd. The shares were sold at an average price of $319.74, for a total value of $567,538.50. Following the completion of the sale, the executive vice president owned 23,406 shares of the company’s stock, valued at $7,483,834.44. The trade was a 7.05% decrease in their position. The SEC filing for this sale provides additional information. Insiders have sold a total of 53,923 shares of company stock worth $18,072,087 in the last 90 days. 1.20% of the stock is currently owned by company insiders.

Institutional Trading of Alnylam Pharmaceuticals

Large investors have recently bought and sold shares of the company. Thematics Asset Management purchased a new position in Alnylam Pharmaceuticals during the second quarter valued at $1,995,000. Mediolanum International Funds Ltd purchased a new stake in shares of Alnylam Pharmaceuticals in the 3rd quarter worth about $11,389,000. Rakuten Investment Management Inc. bought a new position in shares of Alnylam Pharmaceuticals in the 3rd quarter worth about $14,205,000. Generali Asset Management SPA SGR increased its stake in shares of Alnylam Pharmaceuticals by 6,368.0% in the 3rd quarter. Generali Asset Management SPA SGR now owns 3,234 shares of the biopharmaceutical company’s stock worth $1,475,000 after acquiring an additional 3,184 shares in the last quarter. Finally, Investment Management Corp of Ontario lifted its position in Alnylam Pharmaceuticals by 35.4% during the 2nd quarter. Investment Management Corp of Ontario now owns 31,521 shares of the biopharmaceutical company’s stock valued at $10,279,000 after acquiring an additional 8,244 shares during the period. 92.97% of the stock is owned by institutional investors.

About Alnylam Pharmaceuticals

Alnylam Pharmaceuticals, Inc (NASDAQ: ALNY) is a biopharmaceutical company focused on the discovery, development and commercialization of RNA interference (RNAi) therapeutics. Founded to translate the scientific discovery of RNAi into new medicines, Alnylam applies small interfering RNA (siRNA) technology to silence disease-causing genes. The company develops therapies designed to provide durable disease modification by targeting underlying genetic drivers across a range of rare and more prevalent conditions.

Alnylam has advanced multiple siRNA-based products into commercialization, initially using lipid nanoparticle delivery and more recently employing GalNAc-conjugate chemistry to enable targeted delivery to the liver with subcutaneous dosing.